The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Role of Matrix β-1,3 Glucan in Antifungal Resistance of Non-albicans Candida Biofilms
Open accessAbstract
Candida biofilm infections pose an increasing threat in the health care setting due to the drug resistance associated with this lifestyle. Several mechanisms underlie the resistance phenomenon. In Candida albicans, one mechanism involves drug impedance by the biofilm matrix linked to β-1,3 glucan. Here, we show this is important for other Candida spp. We identified β-1,3 glucan in the matrix, found that the matrix sequesters antifungal drug, and enhanced antifungal susceptibility with matrix β-1,3 glucan hydrolysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“C. glabrata biofilms display antifungal resistance, and are characterized by a compact dense structure of yeast cells nested in an extracellular matrix which is composed of high levels of proteins and carbohydrates including β-1,3 glucan [50,51,52].”
From Candida glabrata: A Lot More Than Meets the Eye (2019) · cites this paper as [52]
In the citing paper
“It is thought that biofilms prevent, to a greater or lesser extent, the penetration of antifungal drugs through their structure, by the establishment of a diffusion barrier, which acts as an ion-exchange resin, binding charged antibiotic molecules, contributing to biofilm drug resistance, including in the case of C. glabrata [44,150,155].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [155]
In the citing paper
“When induced, the disruption of β-1,3-glucans or a β-1,3-glucanase treatment have been shown to increase susceptibility of biofilms to fluconazole and the addition of exogenous β-1,3 glucans has been demonstrated to result in the rise of resistance to fluconazole in planktonic cells [155].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [155]
In the citing paper
“Thus, treatment of biofilms with β-1,3-glucanase increases the susceptibility of biofilms to fluconazole (130), and addition of exogenous β-1,3-glucans increases the tolerance of planktonic cells to fluconazole (122).”
From Candida albicans Biofilms and Human Disease (2015) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious Diseases Society of America
Enders, J. F. (1969) · The Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,296
Chandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Candida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055
Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., & Azeredo, J. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00278.x · Cited by 969
Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms
Ramage, G., Vande Walle, K., Wickes, B. L., & López-Ribot, J. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2475-2479.2001 · Cited by 753
Ramage, G., Rajendran, R., Sherry, L., & Williams, C. (2012) · International Journal of Microbiology · doi:10.1155/2012/528521 · Cited by 583
Al-Fattani, M. A., & Douglas, L. J. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46569-0 · Cited by 548
Candida albicans Biofilms Produce Antifungal-Tolerant Persister Cells
LaFleur, M. D., Kumamoto, C. A., & Lewis, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00684-06 · Cited by 521
Mukherjee, P. K., Chandra, J., Kuhn, D. M., & Ghannoum, M. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4333-4340.2003 · Cited by 511
Cited by
Sorted by citations
Items 101–104 of 104
Ghosh, S., Sarkar, S., Garai, P., Maiti, A. K., Saha, N. C., & Banerjee, P. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-07493-1
From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression
Jerez, J. R., Ambrosio, M. V., Fernandes, M. E. O., & Mima, E. G. D. O. (2026) · MicrobiologyOpen · doi:10.1002/mbo3.70353 · Cited by 1
Molecular mechanisms, pathogenesis and therapeutic advances of Candida albicans in oral candidiasis
Sahu, B. K., Debta, P., Patra, S. K., Sahu, M. C., Mohanta, T. K., & Panda, S. K. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1918424
Grossman, N. T., & Casadevall, A. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00915-26
Metadata
- Authors
- Mitchell, K. F., Taff, H. T., Cuevas, M. A., Reinicke, E. L., Sanchez, H., & Andes, D. R.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Puerto Rico at Cayey (PR)
- University of Wisconsin, Madison, Wisconsin, USA
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-04
- Volume
- 57
- Issue
- 4
- Pages
- 1918-1920
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3623361
- OpenAlex
- W2122010658
- Cited by
- 104
- References
- 24
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 8 · 2021: 4 · 2020: 7 · 2019: 9 · 2018: 5 · 2017: 15 · 2016: 10 · 2015: 11 · 2014: 10 · 2013: 4
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (T32GM008692)
- National Institute of Allergy and Infectious Diseases (NIH R01 AI073289-01, R01AI073289)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- β-1,3-glucan, Candida biofilms, non-albicans Candida, antifungal resistance, biofilm matrix, antifungal susceptibility, glucan hydrolysis
- MeSH terms
- Antifungal Agents, Candida albicans, Proteoglycans, Biofilms, Drug Resistance, Fungal, beta-Glucans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
